SHORT MINI-FUTURE - GENMAB | Delayed Deutsche Boerse AG 01:52:59 2024-07-17 pm EDT | ||
| 22.25 EUR | +0.95% |
|
| Current month | -5.45% | ||
| 1 month | -0.94% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 22.25 | +0.95% |
| 24-07-16 | 22.04 | -1.56% |
| 24-07-15 | 22.39 | +2.19% |
| 24-07-12 | 21.91 | -3.01% |
| 24-07-11 | 22.59 | -2.17% |
Delayed Quote Deutsche Boerse AG
Last update July 17, 2024 at 01:52 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VQ9JYJ |
| ISIN | DE000VQ9JYJ7 |
| Date issued | 2021-07-13 |
| Strike | 3,494 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 13.93 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 24.16 € |
|---|---|
| Lowest since issue | 2.63 € |
| Spread | 0.52 € |
| Spread % | 2.28% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,828
DKK
Average target price
2,446
DKK
Spread / Average Target
+33.83%
- Stock Market
- Certificates
- Certificat
